دورية أكاديمية
Allogeneic Hematopoietic Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm:a CIBMTR analysis
| العنوان: | Allogeneic Hematopoietic Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm:a CIBMTR analysis |
|---|---|
| المؤلفون: | Murthy, Hemant S, Zhang, Mei-Jie, Chen, Karen, Ahmed, Sairah, Deotare, Uday, Ganguly, Siddhartha, Kansagra, Ankit, Michelis, Fotios V, Nishihori, Taiga, Patnaik, Mrinal M, Abid, Muhammad Bilal, Aljurf, Mahmoud, Arai, Yasuyuki, Bacher, Ulrike, Badar, Talha, Badawy, Sherif M, Ballen, Karen, Battiwalla, Minoo, Beitinjaneh, Amer, Bejanyan, Nelli, Bhatt, Vijaya R, Brown, Valerie Inez, Martino, Rodrigo, Cahn, Jean-Yves, Castillo, Paul, Cerny, Jan, Chhabra, Saurabh, Copelan, Edward A, Daly, Andrew, Dholaria, Bhagirathbhai, Diaz, Miguel Angel, Freytes, César O, Grunwald, Michael R, Hashmi, Shahrukh, Hildebrandt, Gerhard C, Jamy, Omer, Joseph, Jacinth, Kanakry, Christopher G, Khera, Nandita, Krem, Maxwell M, Kuwatsuka, Yachiyo, Lazarus, Hillard M, Lekakis, Lazaros J, Liu, Hongtao, Modi, Dipenkumar, Munshi, Pashna, Mussetti, Alberto, Palmisiano, Neil, Patel, Sagar S, Rizzieri, David A, van der Poel, Marjolein, Saber, W. |
| المصدر: | Murthy , H S , Zhang , M-J , Chen , K , Ahmed , S , Deotare , U , Ganguly , S , Kansagra , A , Michelis , F V , Nishihori , T , Patnaik , M M , Abid , M B , Aljurf , M , Arai , Y , Bacher , U , Badar , T , Badawy , S M , Ballen , K , Battiwalla , M , Beitinjaneh , A , Bejanyan , N , Bhatt , V R , Brown , V I , Martino , R , .... |
| سنة النشر: | 2023 |
| المجموعة: | Maastricht University Research Publications |
| الوصف: | Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with a poor prognosis and considered incurable with standard conventional chemotherapy. Small observational studies have shown that allogeneic hematopoietic cell transplantation (allo-HCT) offers durable remissions in patients with BPDCN. We conducted an analysis of 164 patients with BPDCN from 78 centers who underwent allo-HCT between 2007-2018 using data reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). Results: Median follow up of survivors was 49 months (range 6-121). 5-year overall survival (OS), disease-free survival (DFS), relapse, and non-relapse (NRM) rates were 51.2% (95% confidence interval [95%CI]: 42.5-59.8%), 44.4% (95%CI: 36.2-52.8%), 32.2% (95%CI: 24.7-40.3%), and 23.3% (95%CI: 16.9-30.4%), respectively. Disease relapse was the most common cause of death. On multivariate analyses, age =60 was predictive for inferior OS (hazard ratio [HR]= 2.16, 95% CI 1.35-3.46, p= 0.001), and higher NRM [HR= 2.19, 95% CI 1.13-4.22, p= 0.02]. Remission status at time of allo-HCT (CR2/PIF/Relapse vs CR1) was predictive of inferior OS [HR= 1.87, 95% CI 1.14-3.06, p= 0.01] and DFS [HR= 1.75, 95% CI 1.11-2.76, p= 0.02]. Use of myeloablative conditioning with total body irradiation (TBI) was predictive for improved DFS and reduced risk of relapse. Conclusion: Allo-HCT is effective in providing durable remissions and long-term survival in BPDCN. Younger age and allo-HCT in CR1 predicted for improved survival, while myeloablative conditioning with TBI predicted for less relapse and improved DFS. Novel strategies incorporating allo-HCT are needed to further improve outcomes. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | https://cris.maastrichtuniversity.nl/en/publications/48b6a95f-5dff-449d-b24f-7a90bc3ba8f5Test |
| DOI: | 10.1182/bloodadvances.2023011308 |
| الإتاحة: | https://doi.org/10.1182/bloodadvances.2023011308Test https://cris.maastrichtuniversity.nl/en/publications/48b6a95f-5dff-449d-b24f-7a90bc3ba8f5Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.27621260 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1182/bloodadvances.2023011308 |
|---|